Global Hidradenitis Suppurativa Market is growing continuously and expected to grow at a CAGR of 5.40% from 2023 to 2032

Market Highlights

The Hidradenitis Suppurativa Market is expected to reach USD 0.96 Billion by 2030 at 5.40% CAGR during the forecast period 2023-2032

The global hidradenitis suppurativa market has been evaluated as a steady growing market and it is expected to continue growing in the near future. Increasing cases of various chronic inflammatory skin diseases are key factor for the market growth. New drug development and introduction of new treatments are also important factors for the market growth.

Major players in hidradenitis suppurativa market:

There are plenty of large and small market players which operate in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US), and others.

Major players of this market are mainly focusing on new product development and launches. They are also preferring investment in R&D that leading to increasing clinical trials. These companies are working with various government as well as non-government organizations, and research centers to derive effective cure for this rare disease.

Product approval is very crucial part for any company. In 2015, American pharmaceutical company got approval for HUMIRA by European Commission as well as US Food and Drug Administration (FDA). HUMIRA can used for effective treatment of moderate to severe Hidradenitis Suppurativa (HS).

Key companies to watch out for:

German biopharmaceutical company InflaRx has initiated the development of new therapeutics and phase II trial with IFX-1. IFX-1 is a first-in-class monoclonal anti-complement C5a antibody that help to treat the patients with severe Hidradenitis Suppurativa (HS).

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hidradenitis Suppurativa Market Research Report

Segmentation:

Global Hidradenitis suppurativa market has been segmented on the basis of skin conditions which comprises of pimples, folliculitis, deep-acne, boils, and, and others. Folliculitis is further sub-segmented into bacterial folliculitis, hot tub folliculitis (pseudomonas folliculitis), barber's itch (pseudofolliculitis barbae), pityrosporum folliculitis, and others. Deep-acne is further sub-segmented into cysts, blackheads, and others. Boils are further sub-segmented into furuncle or carbuncle, cystic acne, pilondial cyst, and others.

On the basis of treatment, the market has been segmented into medications, surgery, laser treatment, Photodynamic Therapy (PDT), and others. Medication is further sub-segmented into antibiotics, antiandrogens, immunosuppressive drugs, hormones, pain medication, zinc supplements, sulphones, retinoids, and others. Surgery is further sub-segmented into Punch debridement, Incision and drainage, surgical removal, issue-sparing excision with electrosurgery, and others.

On the basis of end user, it is segmented into hospitals, dermatology clinics, medical research centers, academic institutes, and others.

Regional Analysis

Considering the global scenario of the hidradenitis suppurativa market, in 2016, Americas was holding the largest market share in global hidradenitis suppurativa. US is dominating and top revenue generator in Americas market that is mainly due to some factors like funding for new FDA approvals and research. European market is the second largest market for hidradenitis suppurativa. Increasing prevalence and growing knowledge of this disease are major driving forces for the growth of Asia Pacific hidradenitis suppurativa market. Middle East and Africa hidradenitis suppurativa market is expected to limited growth it is mostly because of limited availability access to the healthcare, lack of knowledge of disorder and treatment, traditional healthcare practices etc.